Q-omics provides the consensus-scored MIR10B profile across patient tissues and cancer cell-line models. MIR10B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR10B is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, MIR10B RNA expression shows 14,256 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KIRC, and THYM as cancer lineages where MIR10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR10B survival associations across molecular data types. MIR10B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR10B RNA expression–survival associations across cancer types. High MIR10B expression shows unfavorable associations in LIHC, LGG, UCEC and UVM, but favorable associations in UCS and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR10B RNA expression.
This table summarizes MIR10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR10B shows lower tumor expression in KIRC, KICH, KIRP, UCEC, BRCA and COAD. The KIRC box plot shows higher MIR10B RNA expression in normal versus tumor tissue (log2 FC = −0.849, t-test p < 0.001).
This table shows molecular features associated with MIR10B in patient tissues and cancer cell lines. In patient samples, MIR10B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
